(Q33965240)

30 July 2017

title

Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis (English)

1 reference

30 July 2017

0 references

Serra-Majem L

5

0 references

author name string

Cobos A

1

1 reference

30 July 2017

Jovell AJ

2

1 reference

30 July 2017

García-Altés A

3

1 reference

30 July 2017

García-Closas R

4

1 reference

30 July 2017

language of work or name

1 reference

1 November 1999

1 reference

30 July 2017

published in

Clinical Therapeutics

1 reference

30 July 2017

volume

21

1 reference

30 July 2017

issue

11

1 reference

30 July 2017

page(s)

1924-1936

1 reference

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986740-5

7 January 2021

Cholesterol reduction and its impact on coronary artery disease and total mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986740-5

7 January 2021

Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986740-5

7 January 2021

Cholesterol reduction yields clinical benefit. A new look at old data

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986740-5

7 January 2021

Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986740-5

7 January 2021

Strategies for the management of hypercholesterolaemia: a systematic review of the cost-effectiveness literature.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986740-5

7 January 2021

Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986740-5

7 January 2021

Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986740-5

7 January 2021

Cost-effectiveness of initial therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to treat hypercholesterolemia in a primary care setting of a managed-care organization

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986740-5

7 January 2021

Dietary lipids and blood cholesterol: quantitative meta-analysis of metabolic ward studies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986740-5

7 January 2021

Efficacy of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in the treatment of patients with hypercholesterolemia: a meta-analysis of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986740-5

7 January 2021

Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986740-5

7 January 2021

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986740-5

7 January 2021

Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphism?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986740-5

7 January 2021

Problems of using modelling in the economic evaluation of health care

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986740-5

7 January 2021

Monitoring compliance in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986740-5

7 January 2021

Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986740-5

7 January 2021

10.1016/S0149-2918(00)86740-5

Identifiers

DOI

1 reference

30 July 2017

1 reference